Evidence map›Paper›PMID 39903434›Full record

ArticleInternational journal of hematology2025

Myelodysplastic neoplasms with repeating TAFRO syndrome-like symptoms.

Kenta Hayashino, Nobuharu Fujii, Tomohiro Nagano, Daisuke Ikeda, Kanako Fujiwara, Risa Hashida, Wataru Kitamura, Hiroki Kobayashi, Takumi Kondo, Keisuke Seike and 6 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kenta HayashinoDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan. pst33f6c@s.okayama-u.ac.jp.ORCID http://orcid.org/0000-0002-8043-7768
Tomohiro NaganoDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Daisuke IkedaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Kanako FujiwaraDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Risa HashidaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Wataru KitamuraDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Hiroki KobayashiDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Takumi KondoDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Keisuke SeikeDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Hideaki FujiwaraDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Noboru AsadaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Daisuke EnnishiCenter for Comprehensive Genomic Medicine, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Keiko FujiiDivision of Clinical Laboratory, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAFRO syndrome is a systemic disease characterized by thrombocytopenia, anasarca, fever, systemic inflammation, reticulin fibrosis, renal insufficiency, and organomegaly. Although the pathogenesis of TAFRO syndrome remains unknown, it may be associated with cytokine storm and abnormal immune function. Herein, we present a case of a 65-year-old man who was diagnosed with myelodysplastic neoplasms (MDS) with repeating TAFRO syndrome-like symptoms. At ages 59 and 63 years, he developed TAFRO syndrome and was treated with immunosuppressive therapy, which improved these symptoms. At age 65 years, he had TAFRO syndrome-like symptoms with pancytopenia, chromosomal abnormalities, and dysplasia. The patient was subsequently diagnosed with MDS and treated with methylprednisolone, rituximab, bortezomib, and tocilizumab. His MDS-related and TAFRO syndrome-like symptoms simultaneously improved following treatment. Although the patient was not diagnosed with MDS at the first and second events, chromosomal abnormalities were detected, revealing increased clonal cells. MDS can be complicated by immune disorders associated with increased malignant clonal cells. Additionally, patients with MDS exhibit hypercytokinemia, including interleukin-6 and vascular endothelial growth factor. This case indicates that increased clonal cells and hypercytokinemia caused by MDS may lead to abnormal immune function and induce TAFRO syndrome-like symptoms.

Indexed as

Myelodysplastic SyndromesAgedAntibodies, Monoclonal, HumanizedBortezomibCastleman DiseaseChromosome AberrationsHumansMaleMethylprednisoloneMiddle AgedRituximabThrombocytopeniaAntibodies, Monoclonal, HumanizedBortezomibMethylprednisoloneRituximabtocilizumabDer(1;7)(q10;p10)HLA-DR 15:01HypercytokinemiaMDSTAFRO syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.